The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

References

• HungerSPLuXDevidasMImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology groupJ Clin Oncol201230141663166922412151
   PubMed Web of Science ®Google Scholar
• MörickeAZimmermannMReiterALong-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000Leukemia201024226528420010625
   PubMed Web of Science ®Google Scholar
• AnnesleyCEBrownPNovel agents for the treatment of childhood acute leukemiaTher Adv Hematol201562617925830014
   PubMed Web of Science ®Google Scholar
• LocatelliFSchrappeMBernardoMERutellaSHow I treat relapsed childhood acute lymphoblastic leukemiaBlood2012120142807281622896001
   PubMed Web of Science ®Google Scholar
• CooperSLBrownPATreatment of pediatric acute lymphoblastic leukemiaPediatr Clin North Am2015621617325435112
   PubMed Web of Science ®Google Scholar
• KoRHJiLBarnettePOutcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium studyJ Clin Oncol201028464865419841326
   PubMed Web of Science ®Google Scholar
• JehaSGaynonPSRazzoukBIPhase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemiaJ Clin Oncol200624121917192316622268
   PubMed Web of Science ®Google Scholar
• von StackelbergALocatelliFZugmaierGPhase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaJ Clin Oncol201634364381438927998223
   PubMed Web of Science ®Google Scholar
• von StackelbergAVölzkeEKühlJSOutcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study GroupEur J Cancer2011471909720970323
   PubMed Web of Science ®Google Scholar
• EshharZBachNFitzer-AttasCJThe T-body approach: potential for cancer immunotherapySpringer Semin Immunopathol19961821992098908700
   PubMed Web of Science ®Google Scholar
• ChmielewskiMHombachAAAbkenHAntigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cellsFront Immunol2013437124273543
   PubMed Web of Science ®Google Scholar
• HustonJSLevinsonDMudgett-HunterMProtein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coliProc Natl Acad Sci U S A19888516587958833045807
   PubMed Web of Science ®Google Scholar
• StancovskiISchindlerDGWaksTYardenYSelaMEshharZTargeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptorsJ Immunol199315111657765827902379
   PubMed Web of Science ®Google Scholar
• FinneyHMLawsonADBebbingtonCRWeirANChimeric receptors providing both primary and costimulatory signaling in T cells from a single gene productJ Immunol19981616279127979743337
   PubMed Web of Science ®Google Scholar
• HombachAWieczarkowieczAMarquardtTTumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor moleculeJ Immunol2001167116123613111714771
   PubMed Web of Science ®Google Scholar
• MaherJBrentjensRJGunsetGRivièreISadelainMHuman T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptorNat Biotechnol2002201707511753365
   PubMed Web of Science ®Google Scholar
• HombachAAChmielewskiMRapplGAbkenHAdoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulationHum Gene Ther201324325926923350854
   PubMed Web of Science ®Google Scholar
• TammanaSHuangXWongM4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesHum Gene Ther2010211758619719389
   PubMed Web of Science ®Google Scholar
• HuWSPathakVKDesign of retroviral vectors and helper cells for gene therapyPharmacol Rev200052449351111121508
   PubMed Web of Science ®Google Scholar
• LevineBLMiskinJWonnacottKKeirCGlobal manufacturing of CAR T cell therapyMol Ther Methods Clin Dev201749210128344995
   PubMed Web of Science ®Google Scholar
• HayKAHanafiLALiDKinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapyBlood2017130212295230628924019
   PubMed Web of Science ®Google Scholar
• TeacheyDTLaceySFShawPAIdentification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaCancer Discov20166666467927076371
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar
• BrentjensRJRivièreIParkJHSafety and persistence of adoptively transferred autologous CD19−targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood2011118184817482821849486
   PubMed Web of Science ®Google Scholar
• CurranKJPegramHJBrentjensRJChimeric antigen receptors for T cell immunotherapy: current understanding and future directionsJ Gene Med201214640541522262649
   PubMed Web of Science ®Google Scholar
• HaynesNMTrapaniJATengMWRejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors code-livering CD28 costimulationJ Immunol2002169105780578612421958
   PubMed Web of Science ®Google Scholar
• FinneyHMAkbarANLawsonADActivation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chainJ Immunol2004172110411314688315
   PubMed Web of Science ®Google Scholar
• HurtadoJCKimYJKwonBSSignals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell deathJ Immunol19971586260026099058792
   PubMed Web of Science ®Google Scholar
• MayKFChenLZhengPLiuYAnti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cellsCancer Res200262123459346512067989
   PubMed Web of Science ®Google Scholar
• ImaiCMiharaKAndreanskyMChimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemiaLeukemia200418467668414961035
   PubMed Web of Science ®Google Scholar
• MogiSSakuraiJKohsakaTTumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cellsImmunology2000101454154711122458
   PubMed Web of Science ®Google Scholar
• BrentjensRJLatoucheJBSantosEEradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15Nat Med20039327928612579196
   PubMed Web of Science ®Google Scholar
• BrentjensRJSantosENikhaminYGenetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenograftsClin Cancer Res20071318 Pt 15426543517855649
   PubMed Web of Science ®Google Scholar
• MiloneMCFishJDCarpenitoCChimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivoMol Ther20091781453146419384291
   PubMed Web of Science ®Google Scholar
• MüschenMLeeSZhouGMolecular portraits of B cell lineage commitmentProc Natl Acad Sci U S A20029915100141001912119411
   PubMed Web of Science ®Google Scholar
• ScheuermannRHRacilaECD19 antigen in leukemia and lymphoma diagnosis and immunotherapyLeuk Lymphoma1995185–63853978528044
   PubMed Web of Science ®Google Scholar
• SchwonzenMPohlCSteinmetzTImmunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classificationBr J Haematol19938322322398457472
   PubMed Web of Science ®Google Scholar
• StamenkovicISeedBCD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tailJ Exp Med19881683120512102459292
   PubMed Web of Science ®Google Scholar
• KalosMLevineBLPorterDLT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaSci Transl Med201139595ra73
   Google Scholar
• PorterDLHwangWTFreyNVChimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaSci Transl Med20157303303ra139
   PubMed Web of Science ®Google Scholar
• GruppSAKalosMBarrettDChimeric antigen receptor-modified T cells for acute lymphoid leukemiaN Engl J Med2013368161509151823527958
   PubMed Web of Science ®Google Scholar
• LeeDWKochenderferJNStetler-StevensonMT cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trialLancet2015385996751752825319501
   PubMed Web of Science ®Google Scholar
• LeeDWStetler-StevensonMYuanCMSafety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemiaBlood201512623684
   Web of Science ®Google Scholar
• MaudeSLTeacheyDTRheingoldSRSustained remissions with CD19−specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALLJ Clin Oncol20163415_suppl3011
   Web of Science ®Google Scholar
• MaudeSLLaetschTWBuechnerJTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemiaN Engl J Med2018378543944829385370
   PubMed Web of Science ®Google Scholar
• FitzgeraldJCWeissSLMaudeSLCytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemiaCrit Care Med2017452e124e13127632680
   PubMed Web of Science ®Google Scholar
• McguirkJWallerEKQayedMBuilding blocks for institutional preparation of CTL019 deliveryCytotherapy20171991015102428754600
   PubMed Web of Science ®Google Scholar
• AllenESStroncekDFRenJAutologous lymphapheresis for the production of chimeric antigen receptor T cellsTransfusion20175751133114128236305
   PubMed Web of Science ®Google Scholar
• QasimWZhanHSamarasingheSMolecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cellsSci Transl Med20179374eaaj201328123068
   PubMed Web of Science ®Google Scholar
• LaurentiLPiccioniPCattaniPCytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovirHaematologica200489101248125215477211
   PubMed Web of Science ®Google Scholar
• GornalusseGGHirataRKFunkSEHLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cellsNat Biotechnol201735876577228504668
   PubMed Web of Science ®Google Scholar
• GardnerRAFinneyOAnnesleyCIntent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adultsBlood2017129253322333128408462
   PubMed Web of Science ®Google Scholar
• SinghNPerazzelliJGruppSABarrettDMEarly memory phenotypes drive T cell proliferation in patients with pediatric malignanciesSci Transl Med20168320320ra3
   PubMed Web of Science ®Google Scholar
• HudecekMSchmittTMBaskarSThe B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorBlood2010116224532454120702778
   PubMed Web of Science ®Google Scholar
• ZhangWYWangYGuoYLTreatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial reportSignal Transduct Target Ther201611600229263894
   PubMed Web of Science ®Google Scholar
• QinHZhangLOrentasRJFryTJCD22-targeted chimeric antigen receptor (CAR) T cells containing the 4-1BB costimulatory domain demonstrate enhanced persistence and superior efficacy against B-cell precursor acute lymphoblastic leukemia (ALL) compared to those containing CD28Blood2013122211431
   Web of Science ®Google Scholar
• QinHChoMHasoWEradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoproteinBlood2015126562963926041741
   PubMed Web of Science ®Google Scholar
• MartyniszynAKrahlACAndréMCHombachAAAbkenHCD20-CD19 bispecific CAR T cells for the treatment of B-cell malignanciesHum Gene Ther201728121147115729207878
   PubMed Web of Science ®Google Scholar
• SchneiderDXiongYWuDA tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell linesJ Immunother Cancer2017514228515942
   PubMed Web of Science ®Google Scholar
• FryTJShahNNOrentasRJCD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19−targeted CAR immunotherapyNat Med2018241202829155426
   PubMed Web of Science ®Google Scholar
• WuCYRoybalKTPuchnerEMOnufferJLimWARemote control of therapeutic T cells through a small molecule-gated chimeric receptorScience20153506258aab407726405231
   PubMed Web of Science ®Google Scholar
• SakemuraRTerakuraSWatanabeKA tet-on inducible system for controlling CD19−chimeric antigen receptor expression upon drug administrationCancer Immunol Res20164865866827329987
   PubMed Web of Science ®Google Scholar
• DiaconuIBallardBZhangMInducible caspase-9 selectively modulates the toxicities of CD19−specific chimeric antigen receptor-modified T cellsMol Ther201725358059228187946
   PubMed Web of Science ®Google Scholar
• FrigaultMJLeeJBasilMCIdentification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cellsCancer Immunol Res20153435636725600436
   PubMed Web of Science ®Google Scholar
• EyquemJMansilla-SotoJGiavridisTTargeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature2017543764311311728225754
   PubMed Web of Science ®Google Scholar
• RuppLJSchumannKRoybalKTCRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cellsSci Rep20177173728389661
   PubMed Web of Science ®Google Scholar
• FraiettaJANoblesCLSammonsMADisruption of TET2 promotes the therapeutic efficacy of CD19−targeted T cellsNature2018558770930731229849141
   PubMed Web of Science ®Google Scholar
• HaoYEldjerouLKYangHQiCGlobeDCost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United StatesBlood2017130Suppl 1609
   Google Scholar
• BattJSMichelleBYanniHThe Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United KingdomBlood2017130Suppl 11330
   Google Scholar
• Rep. Doggett Calls for Transparency in New Cancer Drug Pricing Agreement2017 Available from: https://doggett.house.gov/media-center/press-releases/rep-doggett-calls-transparency-new-cancer-drug-pricing-agreementAccessed July 26, 2018
   Google Scholar
• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• Cancer2018 Available from: http://www.who.int/news-room/fact-sheets/detail/cancerAccessed May 31, 2018
   Google Scholar
• DolginEBringing down the cost of cancer treatmentNature20185557695S26S2929517030
   PubMed Web of Science ®Google Scholar
• BarlasSAre specialty drug prices destroying insurers and hurting consumers? A number of efforts are under way to reduce price pressureP T201439856356625136254
   PubMedGoogle Scholar
• Kymriah® (tisagenlecleucel)first-in-class CAR-T therapy from Novartis-receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma Novartis2018 Available from: https://www.novartis.com/news/media-releases/kymriahr-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphomaAccessed July 26, 2018
   Google Scholar
• ChandraAGarthwaiteCThe Economics of Indication-Based Drug Pricing; 2017N Engl J Med2017377210310628700848
   PubMed Web of Science ®Google Scholar
• Tisagenlecleucel (Kymriah) Approved to Treat Some Lymphomas –National Cancer Institute2018 Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphomaAccessed May 31 2018
   Google Scholar
• Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah (TM) (CTL019)For children and young adults with B-cell ALL that is refractory or has relapsed at least twice|Novartis2018 Available from: https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019Accessed May 31, 2018
   Google Scholar
• CMS: Innovative treatments call for innovative payment models and arrangements2018 Available from: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2017-Press-releases-items/2017-08-30-2.htmlAccessed May 31, 2018
   Google Scholar
• CMS Fast Facts2018 Available from: https://www.cms.gov/fastfacts/Accessed July 26, 2018
   Google Scholar
• CastilloEFormal Request for National Coverage Determination for Chimeric Antigen Receptor T-Cell Therapies2018 Available from: https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id291.pdf
   Google Scholar
• Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and ValueInstitute for Clinical and Economic Review2018
   Google Scholar
• NeumannPJCohenJTWeinsteinMCUpdating Cost-Effectiveness – The Curious Resilience of the $50,000-per-QALY ThresholdN Engl J Med2014371979679725162885
   PubMed Web of Science ®Google Scholar
• BaileyLCLangeBJRheingoldSRBuninNJBone-marrow relapse in paediatric acute lymphoblastic leukaemiaLancet Oncol20089987388318760243
   PubMed Web of Science ®Google Scholar